导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -3.59% | 3255/4773 |
| 近一周 | -1.38% | 2101/5465 |
| 近一月 | -6.74% | 4306/5421 |
| 近一季 | 9.76% | 207/5231 |
| 近半年 | -2.78% | 2275/4920 |
| 近一年 | -15.59% | 3758/4394 |
| 近两年 | 16.37% | 2711/2954 |
| 近三年 | -11.71% | 2053/2253 |
| 成立以来 | -11.17% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-1.58% 2373/4961 |
-6.18% 3668/5312 |
- - |
- - |
| 2025 | 4.69% 3037/4813 |
0.68% 1794/3635 |
1.94% 2004/4076 |
16.00% 2736/4524 |
-12.06% 4240/4813 |
| 2024 | -12.10% 2365/3463 |
-10.68% 2366/2808 |
-8.79% 2285/3014 |
18.65% 971/3129 |
-9.07% 2902/3463 |
| 2023 | -11.34% 1392/2656 |
0.08% 1764/2280 |
-7.60% 1873/2385 |
-1.64% 559/2515 |
-2.52% 487/2655 |
| 2022 | -21.21% 1019/2207 |
-12.55% 633/1919 |
-0.37% 1620/2016 |
-16.96% 1531/2113 |
8.89% 248/2208 |
| 2021 | -11.79% 1116/1822 |
-3.65% 819/1255 |
13.84% 276/1330 |
-15.05% 1379/1466 |
-5.33% 1508/1822 |
| 2020 | 47.88% 191/1250 |
5.92% 50/1028 |
28.00% 118/1067 |
3.48% 981/1164 |
5.41% 786/1184 |
| 2019 | - - |
- - |
-1.63% 315/788 |
4.78% 180/850 |
3.99% 820/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 汇添富中证医药ETF联接C VS. 长安沪深300非周期A(740101) |